NEW YORK, Nov. 11, 2016 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cempra, Inc. ("Cempra" or the "Company") (NASDAQ: CEMP) and certain of its officers. The class action, filed in United States District Court, Middle District of North Carolina, and docketed under 16-cv-1303, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Cempra securities between May 1, 2016 and November 1, 2016, both dates inclusive (the "Class Period"), seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934. If you are a shareholder who purchased Cempra securities during the Class Period, you have until January 3, 2017 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at firstname.lastname@example.org or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. [Click here to join this class action] Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. One of the Company's lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) solithromycin posed significant safety risks for hepatotoxicity; and (ii) as a result of the foregoing, Cempra' public statements were materially false and misleading at all relevant times.